HK1 and fragile X syndrome: To address this possibility, we examined a larger panel of the potential biomarkers and found that three, HK1, RAS, and ACO2, exhibit clear population differences in abundance between control and FXS patients, whereas candidates such as Grin2B, BNDF and mGluR5 show stratified expression levels (Supplementary Fig. 8).